ULURU Inc. (NYSE Alternext: ULU) today announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented nine clinical posters at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" being held in San Antonio, Texas.
Highlights of the clinical experience presented by Dr. Bohn's poster presentations include:
- A stagnated traumatic wound that was treated with Altrazeal(TM) eliminated the need for a skin graft procedure
- Using Altrazeal(TM) in combination with total contact casts decreased "days to heal" from 41 days to 15 days in Wagner grade 2 neuropathic diabetic foot ulcers
- Chronic venous stasis ulcer patients that had not healed in 30 months after treatments including skin graft and bioengineered skin graft healed after treatment with Altrazeal(TM)
Commenting on Altrazeal(TM), Dr. Gregory Bohn stated, "Altrazeal(TM) can be a work horse in the wound care field. I have seen dramatic clinical results on many different types of problematic wounds. I have also found that Altrazeal(TM) increases wound care dressing wear time which has been instrumental in increasing patients' treatment compliance and enabling costs to be constrained within Medicare monthly limits for stomal and wound care supplies. Additionally, combining Altrazeal(TM) with contact casts for Wagner grade 2 diabetic foot ulcers has reduced our days to heal from 41 days to 15.2 days representing a substantial cost savings and avoiding morbidity for our diabetic patients."
Also included in the poster presentations by Dr. Bohn was evidence of the benefits of using Altrazeal(TM), including: